Medtronic plc — Form 10-Q Summary
Reporting period: Three months ended July 30, 2021, Medtronic’s first quarter of fiscal 2022. The filing compares results with the three months ended July 31, 2020. Unless stated otherwise, amounts are U.S. dollars.
Business context and results
Medtronic sells medical devices, therapies, and related services across Cardiovascular, Medical Surgical, Neuroscience, and Diabetes. Management said most businesses were at or above pre-pandemic levels, as procedure volumes recovered from the prior-year downturn. COVID-19’s effects remained uncertain; elective procedures slowed in some markets, including parts of the U.S. late in July amid the Delta variant.
| Metric | Q1 FY2022 | Q1 FY2021 |
|---|---|---|
| Net sales | $7.987 billion | $6.507 billion |
| Operating profit (GAAP) | $859 million | $673 million |
| Net income attributable to Medtronic | $763 million | $487 million |
| Diluted EPS (GAAP) | $0.56 | $0.36 |
| Operating cash flow | $1.292 billion | $278 million |
| Free cash flow (non-GAAP) | $914 million | $(56) million |
Sales increased 23% year over year; favorable currency translation contributed $245 million. GAAP gross margin was approximately 67.5%, compared with 61.5%; GAAP operating margin was approximately 10.8%, compared with 10.3%. These comparisons are affected by unusual items, notably the current-period HVAD charges and prior-year items. Adjusted diluted EPS was $1.41 versus $0.62, on the company’s non-GAAP basis.
Segment sales: Cardiovascular $2.890 billion (+19%); Medical Surgical $2.322 billion (+29%); Neuroscience $2.204 billion (+29%); and Diabetes $572 million (+2%). The company attributed broad growth primarily to procedure-volume recovery; Diabetes growth was partly offset by U.S. competition.
Cash, debt, and liquidity
At July 30, 2021, cash and cash equivalents were $3.004 billion and current investments were $7.591 billion. Current assets were $22.434 billion and current liabilities $7.764 billion. Total debt was approximately $26.0 billion, down from $26.4 billion at April 30, 2021. No commercial paper or revolving-credit-facility borrowings were outstanding; the facility was $3.5 billion. Management said available liquidity and credit resources were expected to meet foreseeable operating needs.
Cash and cash equivalents declined by $589 million during the quarter. Investing activities used $784 million and financing activities used $1.055 billion, including $846 million of dividends and $315 million of share repurchases. The quarterly dividend was $0.63 per share.
Material changes and unusual items
- HVAD exit: Medtronic stopped distribution and sale of its HVAD heart-pump system on June 3, citing observational comparisons indicating lower neurological adverse-event and mortality frequency with another available device. It recorded $726 million in charges, including $515 million of noncash impairments and inventory write-downs. Accruals for related obligations were $171 million at quarter-end; the company said it would continue supporting approximately 4,000 implanted patients.
- Other earnings factors: The GAAP effective tax rate was 7.7%, versus 15.9%, primarily reflecting the tax impact of HVAD charges and jurisdictional results, partly offset by a $39 million tax charge related to a change in the permanent-reinvestment assertion. Other operating expense was $760 million, compared with $114 million of income in the prior-year quarter; the prior period included a $132 million acquisition-related gain.
- Investments and R&D: The quarter included $90 million of acquired in-process R&D expensed. Gains on equity and other investments contributed to non-operating income.
- Acquisition announced after quarter-end: On August 6, 2021, Medtronic agreed to acquire Intersect ENT for $28.25 per share in an all-cash transaction valued at approximately $1.1 billion, subject to approvals and other conditions.
Outlook, risks, and contingencies
The filing does not provide a specific near-term revenue or EPS forecast. Management expected procedure rates to remain uneven by therapy and geography, with COVID-19 cases, vaccination levels, and new variants affecting demand. Risks cited include competition and pricing pressure, supply constraints, regulatory delays or actions, reimbursement changes, currency movements, cybersecurity incidents, and acquisition execution.
Medtronic projected annual savings of approximately $500–$700 million through fiscal 2022 from its Enterprise Excellence program, and approximately $450–$475 million from Simplification. Most remaining restructuring charges were expected by the end of fiscal 2022. The company also noted product and regulatory matters, including the Valiant Navion voluntary recall and its plans to ramp production of the prior-generation Captivia system.
Legal exposures include product-liability, patent, environmental, and tax matters. Accrued litigation was approximately $300 million. A court decision remained pending in a long-running IRS dispute over income allocation involving Puerto Rico operations; gross unrecognized tax benefits were $1.7 billion. The filing cautions that outcomes and potential impacts of certain matters may be material but are difficult to estimate.
Most important facts for investors to verify
- Whether procedure-volume recovery and revenue growth persist, particularly if COVID-19 or the Delta variant disrupts elective care.
- The ongoing financial, patient-support, and legal consequences of discontinuing HVAD, and progress on the Valiant Navion recall and production transition.
- How much of reported earnings and cash flow reflects recurring operations versus impairments, restructuring, investment gains, and other adjustments; review the company’s non-GAAP reconciliations.
- Progress in realizing stated restructuring savings and the remaining associated costs.
- Developments in litigation and tax proceedings, including the Puerto Rico transfer-pricing dispute and the scale of unrecognized tax benefits.
- Whether the Intersect ENT acquisition closes on the announced terms and how it affects capital allocation and liquidity.